NasdaqGS - Nasdaq Real Time Price USD

Kiniksa Pharmaceuticals International, plc (KNSA)

25.97

+4.50

+(20.96%)

As of 3:24:51 PM EDT. Market Open.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 450% and 7.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 hours ago

KNSA
+20.96%
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWS

GlobeNewswire 7 hours ago

KNSA
+20.96%
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may registe

GlobeNewswire 4 days ago

KNSA
+20.96%
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 8 days ago

QURE

KNSA
+20.96%
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?

Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 19 days ago

KNSA
+20.96%
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year.

Zacks 21 days ago

KNSA
+20.96%
KRYS
+0.66%
Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 25 days ago

KNSA
+20.96%
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

KNSA
+20.96%
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer healthcare stocks to buy with $1,000 right now. AbbVie's product lineup is led by blockbuster drugs targeting autoimmune diseases, with Rinvoq and Skyrizi delivering especially strong sales growth.

Motley Fool last month

ABBV

VRTX

KNSA
+20.96%
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?

We recently compiled a list of the 10 Best UK Growth Stocks to Buy Now. In this article, we are going to take a look at where Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) stands against the other UK growth stocks. The start of this year has marked interesting developments for the UK market. The main stock market […]

Insider Monkey last month

KNSA
+20.96%
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock

Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks last month

KNSA
+20.96%
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks last month

KNSA
+20.96%
PTCT
Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks last month

KNSA
+20.96%
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now?

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) stands against the other small cap pharma stocks. Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical Industry Emily Field, Head […]

Insider Monkey last month

KNSA
+20.96%
US High Growth Tech Stocks With Strong Potential

Over the last 7 days, the United States market has dropped 4.8%, yet it has risen by 15% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential through innovation and adaptability to leverage these market dynamics effectively.

Simply Wall St. last month

KNSA
+20.96%
FOLD

VNDA
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -100% and 0.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

KNSA
+20.96%
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Abiprubart development in Sjögren’s Disease to be discontinued –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webc

GlobeNewswire 2 months ago

KNSA
+20.96%
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascending dose data support potential monthly dosing – – Kiniksa continues to focus development on diseases with unmet need, prioritizing cardiovascular indications – – Kiniksa to discontinue abiprubart development in Sjögren’s Disease – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical

GlobeNewswire 2 months ago

KNSA
+20.96%
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution.A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telep

GlobeNewswire 2 months ago

KNSA
+20.96%
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s potential.

The Wall Street Journal 2 months ago

KNSA
+20.96%

Performance Overview

Return	KNSA	S&P 500 (^GSPC)
YTD	+31.29%	-5.36%
1-Year	+40.00%	+8.80%
3-Year	+178.35%	+34.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?

Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now?

US High Growth Tech Stocks With Strong Potential

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles

Performance Overview